Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (4): 661-666. doi: 10.19723/j.issn.1671-167X.2024.04.019

Previous Articles     Next Articles

Clinicopathological characteristics and prognosis of multilocular cystic renal neoplasm of low malignant potential

Le YU,Shaohui DENG,Fan ZHANG,Ye YAN,Jianfei YE,Shudong ZHANG*()   

  1. Department of Urology, Peking University Third Hospital, Beijing 100191, China
  • Received:2024-03-15 Online:2024-08-18 Published:2024-07-23
  • Contact: Shudong ZHANG E-mail:zhangshudong@bjmu.edu.cn
  • Supported by:
    the National Natural Science Foundation of China(82273389)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To analyze the clinicopathological characteristics and prognosis of patients with multilocular cystic renal neoplasm of low malignant potential and compare the clinicopathological characteristics of patients with multilocular cystic renal neoplasm of low malignant potential who underwent different surgical methods. Methods: Clinicopathological data and prognosis of patients admitted to Peking University Third Hospital from January 2010 to September 2023 were collected. Patients who underwent radical nephrectomy or nephron-sparing surgery and were pathologically diagnosed with multilocular cystic renal neoplasm of low malignant potential were identified. Based on the surgical methods, the patients were divided into radical nephrectomy group and nephron-sparing surgery group. The clinicopathological characteristics of the two groups were compared. Results: A total of 35 patients were enrolled in this study. The median age at diagnosis was 53.0 (39.0-62.0) years. Among the 35 patients, 23 were males (65.7%) and 12 were females (34.3%). Nine patients underwent radical nephrectomy (25.7%), while 26 patients underwent nephron-sparing surgery (74.3%). The clinical T-stage of 35 patients did not exceed T2a stage. The median operation time was 145.0 min, and the median estimated intraoperative blood loss was 20.0 mL. The median postoperative hospitalization days was 6.0 d. The postoperative pathological results did not indicate renal sinus invasion, sarcomatous change, adrenal invasion or lymph node invasion. Based on the surgical methods, the patients were divided into a radical nephrectomy group and a nephron-sparing surgery group. There was no significant difference in clinicopathological charac-teristics between the two groups. Except for one patient who was lost to the follow-up, all the other patients were followed up for 8-111 months, with a median follow-up time of 70.5 months. Only one patient died from non-cancer-specific reasons, other patients had no tumor metastasis or recurrence. Conclusion: Patients with multilocular cystic renal neoplasm of low malignant potential have a good prognosis. There is no significant difference in clinicopathological characteristics of patients between nephron-sparing surgery group and radical nephrectomy group for multilocular cystic renal neoplasm of low malignant potential.

Key words: Renal neoplasm, Nephron-sparing surgery, Prognosis

CLC Number: 

  • R737.1

Figure 1

Inclusion and exclusion criteria and the final number of patients in the study MCRNLMP, multilocular cystic renal neoplasm of low malignant potential."

Table 1

Clinicopathological characteristics of MCRNLMP patients"

Items MCRNLMP (n=35)
Age/years, M (P25, P75) 53.0 (39.0, 62.0)
Gender, n (%)
  Male 23 (65.7)
  Female 12 (34.3)
BMI/(kg/m2), M (P25, P75) 24.5 (22.6, 27.7)
Hypertension, n (%) 14 (40.0)
Diabetes, n (%) 6 (17.1)
History of operation, n (%) 15 (42.9)
Laterality, n (%)
  Left 19 (54.3)
  Right 16 (45.7)
Tumor diameter/ cm, M (P25, P75) 4.6 (3.7, 7.0)
Clinical T stage, n (%)
  T1a 14 (40.0)
  T1b 14 (40.0)
  T2a 7 (20.0)
Surgical method, n (%)
  RN 9 (25.7)
  NS 26 (74.3)
Preoperative HGB/(g/L), M (P25, P75) 148.0 (131.0, 154.0)
Preoperative Plt /(g/L), M (P25, P75) 206.0 (172.0, 293.0)
Preoperative WBC count /(×109), M (P25, P75) 5.6 (5.2, 6.6)
Preoperative ALB /(g/L), M (P25, P75) 44.4 (41.5, 46.4)
Preoperative SCr / (μmol/L), M (P25, P75) 80.0 (68.0, 87.0)
Preoperative eGFR/ [mL/(min·1.73 m2)], M (P25, P75) 94.3 (74.1, 118.3)
Operation time/min, M (P25, P75) 145.0 (123.0, 217.0)
Estimated blood loss/mL, M (P25, P75) 20.0 (10.0, 50.0)
Postoperative SCr / (μmol/L), M (P25, P75) 90.0 (80.0, 109.0)
Postoperative eGFR/ [mL/(min·1.73 m2)], M (P25, P75) 82.3 (61.6, 109.5)
Postoperative hospitalization / d, M (P25, P75) 6.0 (5.0, 8.0)
Pathology, n (%)
  Sarcomatous change 0 (0)
  Lymph node invasion 0 (0)
  Adrenal gland invasion 0 (0)
  Renal sinus invasion 0 (0)
Postoperative complications, n (%) 9 (25.7)
Serious complications, n (%) 1 (2.9)

Table 2

Comparison of two groups of MCRNLMP patients"

Items NS (n=26) RN (n=9) P value
Age/years, M (P25, P75) 53.0 (34.5, 64.3) 51.5 (42.0, 55.5) 0.52
Gender, n (%) 0.64
  Male 17 (65.4) 6 (66.7)
  Female 9 (34.6) 3 (33.3)
BMI/(kg/m2), M (P25, P75) 24.3 (22.5, 27.4) 24.2 (21.5, 25.8) 0.84
Hypertension, n (%) 8 (30.7) 6 (66.7) 0.11
Diabetes, n (%) 4 (15.4) 2 (22.2) 0.64
History of operation, n (%) 9 (34.6) 6 (66.7) 0.13
Laterality, n (%) 0.99
  Left 14 (53.8) 5 (55.6)
  Right 12 (46.2) 4 (44.4)
Tumor diameter/ cm, M (P25, P75) 4.3 (3.7, 7.3) 5.3 (3.2, 6.7) 0.22
Clinical T stage, n (%) 0.22
  T1a 12 (46.2) 2 (22.2)
  T1b 8 (30.8) 6 (66.7)
  T2a 6 (23.1) 1 (11.1)
Preoperative HGB/(g/L), M (P25, P75) 147.5 (132.5, 154.8) 140.5 (124.3, 153.3) 0.29
Preoperative Plt/(g/L), M (P25, P75) 207.5 (187.0, 295.0) 210.0 (161.5, 314.0) 0.87
Preoperative WBC count/(×109), M (P25, P75) 5.5 (5.0, 6.6) 6.4 (5.3, 6.6) 0.75
Preoperative ALB/(g/L), M (P25, P75) 45.4 (41.9, 46.7) 43.7 (40.9, 45.5) 0.31
Preoperative SCr/(μmol/L), M (P25, P75) 80.0 (68.3, 87.5) 76.5 (64.3, 96.5) 0.93
Preoperative eGFR/[mL/(min·1.73 m2)], M (P25, P75) 94.2 (79.1, 117.4) 94.3 (54.9, 134.5) 0.78
Operation time/min, M (P25, P75) 134.5 (123.3, 182.5) 212.0 (99.3, 227.8) 0.59
Estimated blood loss/mL, M (P25, P75) 22.5 (10.0, 100.0) 20.0 (15.0, 50.0) 0.57
Postoperative SCr/(μmol/L), M (P25, P75) 82.5 (74.0, 99.3) 115.5 (99.3, 134.8) 0.32
Postoperative eGFR/[mL/(min·1.73 m2)], M (P25, P75) 86.7 (72.8, 109.9) 58.4 (46.2, 84.6) 0.92
Postoperative hospitalization/d, M (P25, P75) 6.0 (5.0, 8.0) 6.0 (4.5, 12.0) 0.57
Postoperative complications, n (%) 7 (26.9) 2 (22.2) 0.99
Serious complications, n (%) 0 (0) 1 (11.1) 0.26
1 Siegel RL , Miller KD , Fuchs HE , et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72 (1): 7- 33.
doi: 10.3322/caac.21708
2 Moch H , Cubilla AL , Humphrey PA , et al. The 2016 WHO classification of tumours of the urinary system and male genital organs. Part A: Renal, penile, and testicular tumours[J]. Eur Urol, 2016, 70 (1): 93- 105.
doi: 10.1016/j.eururo.2016.02.029
3 Li T , Chen J , Jiang Y , et al. Multilocular cystic renal cell neoplasm of low malignant potential: A series of 76 cases[J]. Clin Genitourin Cancer, 2016, 14 (6): e553- e557.
doi: 10.1016/j.clgc.2016.03.017
4 Westerman ME , Cheville JC , Lohse CM , et al. Long-term outcomes of patients with low grade cystic renal epithelial neoplasms[J]. Urology, 2019, 133, 145- 150.
doi: 10.1016/j.urology.2019.07.017
5 Suzigan S , López-Beltrán A , Montironi R , et al. Multilocular cystic renal cell carcinoma: A report of 45 cases of a kidney tumor of low malignant potential[J]. Am J Clin Pathol, 2006, 125 (2): 217- 222.
doi: 10.1309/AH6FC77PYR2V6YAY
6 Kashan M , Ghanaat M , Hötker AM , et al. Cystic renal cell carcinoma: A report on outcomes of surgery and active surveillance in patients retrospectively identified on pretreatment imaging[J]. J Urol, 2018, 200 (2): 275- 282.
doi: 10.1016/j.juro.2018.02.3087
7 Silverman SG , Pedrosa I , Ellis JH , et al. Bosniak classification of cystic renal masses, version 2019: An update proposal and needs assessment[J]. Radiology, 2019, 292 (2): 475- 488.
doi: 10.1148/radiol.2019182646
8 Alrumayyan M , Raveendran L , Lawson KA , et al. Cystic renal masses: Old and new paradigms[J]. Urol Clin North Am, 2023, 50 (2): 227- 238.
doi: 10.1016/j.ucl.2023.01.003
9 Yang B , Sun L , Cao WF , et al. Clear cell renal cell carcinoma with cystic component similar to multilocular cystic renal neoplasm of low malignant potential: A rare pattern of cyst-dependent progression from multilocular cystic renal neoplasm of low malignant potential[J]. Diagn Pathol, 2023, 18 (1): 27.
doi: 10.1186/s13000-023-01315-x
10 Pini GM , Lucianò R , Colecchia M . Cystic clear cell renal cell carcinoma: A morphological and molecular reappraisal[J]. Can-cers (Basel), 2023, 15 (13): 3352.
doi: 10.3390/cancers15133352
11 Kim SH , Park WS , Chung J . SETD2, GIGYF2, FGFR3, BCR, KMT2C, and TSC2 as candidate genes for differentiating multi-locular cystic renal neoplasm of low malignant potential from clear cell renal cell carcinoma with cystic change[J]. Investig Clin Urol, 2019, 60 (3): 148- 155.
doi: 10.4111/icu.2019.60.3.148
12 Raspollini MR , Castiglione F , Martignoni G , et al. Unlike in clear cell renal cell carcinoma, KRAS is not mutated in multilocular cystic clear cell renal cell neoplasm of low potential[J]. Virchows Arch, 2015, 467 (6): 687- 693.
doi: 10.1007/s00428-015-1859-8
13 Shan K , Fu A , Liu N , et al. Contrast-enhanced ultrasound (CEUS) vs contrast-enhanced computed tomography for multilocular cystic renal neoplasm of low malignant potential: A retrospective analysis for diagnostic performance study[J]. Medicine (Baltimore), 2020, 99 (46): e23110.
doi: 10.1097/MD.0000000000023110
14 Bhatt JR , Jewett MA , Richard PO , et al. Multilocular cystic renal cell carcinoma: Pathological T staging makes no difference to favorable outcomes and should be reclassified[J]. J Urol, 2016, 196 (5): 1350- 1355.
doi: 10.1016/j.juro.2016.05.118
15 Nassir A , Jollimore J , Gupta R , et al. Multilocular cystic renal cell carcinoma: A series of 12 cases and review of the literature[J]. Urology, 2002, 60 (3): 421- 427.
doi: 10.1016/S0090-4295(02)01742-9
16 Gong K , Zhang N , He Z , et al. Multilocular cystic renal cell carcinoma: An experience of clinical management for 31 cases[J]. J Cancer Res Clin Oncol, 2008, 134 (4): 433- 437.
doi: 10.1007/s00432-007-0302-1
17 Pitra T , Pivovarcikova K , Alaghehbandan R , et al. A comprehensive commentary on the multilocular cystic renal neoplasm of low malignant potential: A urologist' s perspective[J]. Cancers (Basel), 2022, 14 (3): 831.
doi: 10.3390/cancers14030831
18 Cao C , Deng S , Wang B , et al. Intraoperative near-infrared Ⅱ window fluorescence imaging-assisted nephron-sparing surgery for complete resection of cystic renal masses[J]. Clin Transl Med, 2021, 11 (10): e604.
doi: 10.1002/ctm2.604
[1] Lingfu ZHANG, Ming CHEN, Xiaoyu ZHAO, Gang WANG, Long CUI, Xiaofeng LING, Lixin WANG, Zhi XU, Limei GUO, Chunsheng HOU. Gross classification of gallbladder cancer with primary lesion limited to the gallbladder wall and its correlation with prognosis and precancerous lesions [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 184-189.
[2] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[3] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
[4] Yaqing MAO, Zhen CHEN, Yao YU, Wenbo ZHANG, Yang LIU, Xin PENG. Impact of type 2 diabetes mellitus on the prognosis of patients with oral squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1089-1096.
[5] Junyong OU,Kunming NI,Lulin MA,Guoliang WANG,Ye YAN,Bin YANG,Gengwu LI,Haodong SONG,Min LU,Jianfei YE,Shudong ZHANG. Prognostic factors of patients with muscle invasive bladder cancer with intermediate-to-high risk prostate cancer [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 582-588.
[6] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[7] Zezhen ZHOU,Shaohui DENG,Ye YAN,Fan ZHANG,Yichang HAO,Liyuan GE,Hongxian ZHANG,Guoliang WANG,Shudong ZHANG. Predicting the 3-year tumor-specific survival in patients with T3a non-metastatic renal cell carcinoma [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 673-679.
[8] Yangyi FANG,Qiang LI,Zhigao HUANG,Min LU,Kai HONG,Shudong ZHANG. Well-differentiated papillary mesothelial tumour of the tunica vaginalis: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 741-744.
[9] Yuanyuan ZENG,Yun XIE,Daonan CHEN,Ruilan WANG. Related factors of euthyroid sick syndrome in patients with sepsis [J]. Journal of Peking University (Health Sciences), 2024, 56(3): 526-532.
[10] Kewei CHEN,Shaohui DENG,Zhuo LIU,Hongxian ZHANG,Lulin MA,Shudong ZHANG. Discussion on the surgical timing of rupture and hemorrhage of renal angiomyolipoma [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 326-331.
[11] Jian-bin LI,Meng-na LYU,Qiang CHI,Yi-lin PENG,Peng-cheng LIU,Rui WU. Early prediction of severe COVID-19 in patients with Sjögren’s syndrome [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1007-1012.
[12] Huan-rui LIU,Xiang PENG,Sen-lin LI,Xin GOU. Risk modeling based on HER-2 related genes for bladder cancer survival prognosis assessment [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 793-801.
[13] Zi-xuan XUE,Shi-ying TANG,Min QIU,Cheng LIU,Xiao-jun TIAN,Min LU,Jing-han DONG,Lu-lin MA,Shu-dong ZHANG. Clinicopathologic features and prognosis of young renal tumors with tumor thrombus [J]. Journal of Peking University (Health Sciences), 2023, 55(5): 802-811.
[14] Han LU,Jian-yun ZHANG,Rong YANG,Le XU,Qing-xiang LI,Yu-xing GUO,Chuan-bin GUO. Clinical factors affecting the prognosis of lower gingival squamous cell carcinoma [J]. Journal of Peking University (Health Sciences), 2023, 55(4): 702-707.
[15] Yun-fei SHI,Hao-jie WANG,Wei-ping LIU,Lan MI,Meng-ping LONG,Yan-fei LIU,Yu-mei LAI,Li-xin ZHOU,Xin-ting DIAO,Xiang-hong LI. Analysis of clinicopathological and molecular abnormalities of angioimmunoblastic T-cell lymphoma [J]. Journal of Peking University (Health Sciences), 2023, 55(3): 521-529.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd